Jeffrey C. Sprecher - Apr 3, 2024 Form 4 Insider Report for Intercontinental Exchange, Inc. (ICE)

Signature
/s/ Octavia N. Spencer, Attorney-in-fact
Stock symbol
ICE
Transactions as of
Apr 3, 2024
Transactions value $
-$20,184,858
Form type
4
Date filed
4/5/2024, 04:30 PM
Previous filing
Feb 23, 2024
Next filing
Jul 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICE Common Stock Options Exercise $2.92M +58.4K +4.95% $50.01* 1.24M Apr 3, 2024 Direct F1
transaction ICE Common Stock Sale -$7.58M -55.3K -4.46% $137.18 1.18M Apr 3, 2024 Direct F1, F2
transaction ICE Common Stock Sale -$429K -3.11K -0.26% $137.83 1.18M Apr 3, 2024 Direct F1, F3, F4, F5
transaction ICE Common Stock Sale -$14.3M -104K -3.76% $137.18 2.67M Apr 3, 2024 CPEX F1, F6
transaction ICE Common Stock Sale -$796K -5.78K -0.22% $137.82 2.66M Apr 3, 2024 CPEX F1, F7, F8
holding ICE Common Stock 81.6K Apr 3, 2024 By spouse F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICE Employee Stock Option (right to buy) Holding Options Exercise $0 -58.4K -50% $0.00 58.4K Apr 3, 2024 Common Stock 58.4K $50.01 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan which was approved and became effective as of August 7, 2023.
F2 The price range for the aggregate amount sold by the direct holder is $136.72 - $137.71. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.
F3 The price range for the aggregate amount sold by the direct holder is $137.72 - $138.04. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.
F4 The common stock number referred in Table I is an aggregate number and represents 1,110,990 shares of common stock and 68,905 unvested performance based restricted stock units for which the performance period has been satisfied. These performance based restricted stock units vest over a three year period, in which 33.33% of the units vest each year. The satisfaction of the 2024 performance based restricted units tied to earnings before interest, taxes, depreciation, and amortization ("EBITDA") and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2025 and will be reported at the time of vesting. The satisfaction of the 2022, 2023 and 2024 total shareholder return performance based restricted stock units and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2025, February 2026 and February 2027 respectively, and will be reported at the time of vesting.
F5 The satisfaction of the performance based restricted stock units granted as Deal Incentive Awards and the corresponding number of shares to be issued pursuant to these awards, will not be determined until December 2026, December 2027 and December 2028 and will be subject to additional time-based vesting conditions and, if applicable, a subsequent one-year holding period.
F6 The price range for the aggregate amount sold by the direct holder is $136.71 - $137.69. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.
F7 The price range for the aggregate amount sold by the direct holder is $137.71 - $138.09. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price.
F8 As previously reported, the reporting person also indirectly owns 2,661,705 shares that are beneficially owned directly by CPEX. The reporting person beneficially owns 100% of the equity interest in CPEX. Additionally, as previously reported, the reporting person indirectly owns shares that are beneficially owned directly by the reporting person's spouse for which the reporting person disclaims beneficial ownership.
F9 As previously reported, the reporting person also indirectly owns 81,570 shares that are beneficially owned directly by the reporting person's spouse for which the reporting person disclaims beneficial ownership.
F10 These options are fully vested.